Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01400490
Recruitment Status : Unknown
Verified July 2011 by Cardiovascular Research Associates.
Recruitment status was:  Active, not recruiting
First Posted : July 22, 2011
Last Update Posted : July 22, 2011
Sponsor:
Collaborator:
Dupont Applied Biosciences
Information provided by:
Cardiovascular Research Associates

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The goal of the study is to test the efficacy of an EPA-enriched oil made by DuPont versus a DHA-enriched oil, a standard fish oil preparation, and olive oil placebo in a double-blind, randomized, placebo-controlled trial. This study will compare the efficacy of 1800 mg/day of EPA versus 1800 mg/day of DHA versus a fish oil product containing 1800 mg of EPA and 1200 mg of DHA/day as compared to olive oil placebo at 6 grams/day over a 6 week period in a parallel arm design study of 120 healthy adults studied in both the fasting and post-prandial state. Safety will be monitored by assessing for adverse reactions, measuring vital signs and a variety of lab tests including a complete metabolic profile and complete blood count. Efficacy will be assessed by measuring changes in fatty acid profile and or fatty acid ratios,as well as by measuring plasma lipids, lipoproteins, and markers of inflammation.

Condition or disease Intervention/treatment Phase
Heart Disease Dietary Supplement: EPA-DHA Study Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Evaluation of the Biologic Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)-Enriched Oils (EPA-DHA Study)
Study Start Date : September 2010
Actual Primary Completion Date : July 2011
Estimated Study Completion Date : September 2011
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: Olive Oil 6 grams/day Dietary Supplement: EPA-DHA Study
6 weeks of dietary supplementation
Active Comparator: DHA 1800 mg/day Dietary Supplement: EPA-DHA Study
6 weeks of dietary supplementation
Active Comparator: EPA 1800 mg/day Dietary Supplement: EPA-DHA Study
6 weeks of dietary supplementation
Active Comparator: Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day Dietary Supplement: EPA-DHA Study
6 weeks of dietary supplementation


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. plasma EPA levels as well as the EPA/DHA ratio and plasma DHA levels as well as the DHA/EPA ratio [ Time Frame: Six weeks ]
    Subjects receiving EPA at 1800 mg/day will have significantly greater plasma EPA levels as well as the EPA/DHA ratio than the placebo group or the group receiving DHA, while the group receiving DHA will have significantly greater increases in plasma DHA levels as well as the DHA/EPA ratio than the placebo group or the group receiving EPA.


Secondary Outcome Measures :
  1. LpPLA2 [ Time Frame: 6 weeks ]
    Subjects receiving the active supplement, especially at the 1800 mg daily dose of EPA will have significant reductions in LpPLA2 as compared to both baseline values and to the placebo group.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male or surgically sterile females between ages 21-70.
  • Body Mass Index of 20-35.
  • Plasma Lipoprotein Associated Phospholipase A2 (LpPLA2) values > 200 ng/ml.

Exclusion Criteria:

  • Competitive exerciser.
  • Current smoker.
  • Those already taking dietary supplements (EPA, DHA, flax seed oil, fish oil, cod liver oil, weight control products, or high doses of vitamin C (>500 mg/day) or vitamin E (>400 mg/day).
  • Those consuming more than 3 oily fish species/week.
  • Those consuming >2 drinks containing alcohol/day.
  • Those taking medications which could affect serum lipids or body weight, or taking coumadin or more than 325 mg/day of aspirin which could effect bleeding time or the coagulation profile.
  • History of a bleeding disorder.
  • History of significant cardiac, renal, hepatic, gastro-intestinal, pulmonary, neoplastic, biliary or endocrine disorders including uncontrolled diabetes, thyroid disease, or hypertension.
  • Plasma LpPLA2 values < 200 ng/ml.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01400490


Locations
Layout table for location information
United States, Massachusetts
Cardiovascular Research Associates
Boston, Massachusetts, United States, 02112
Sponsors and Collaborators
Cardiovascular Research Associates
Dupont Applied Biosciences
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Michael L. Dansinger, MD, Cardiovascular Research Associates
ClinicalTrials.gov Identifier: NCT01400490    
Other Study ID Numbers: CVRA 2010-01
First Posted: July 22, 2011    Key Record Dates
Last Update Posted: July 22, 2011
Last Verified: July 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Cardiovascular Diseases